Literature DB >> 6413667

Prospective study of fatty acid supplementation over 3 years in patients with cystic fibrosis.

E Kusoffsky, B Strandvik, S Troell.   

Abstract

Intravenous fatty acid supplementation (10% Intralipid, 10 ml/kg body weight) was given to 10 patients with cystic fibrosis (CF), in intervals for 3 years. One year of intensive treatment with supplementation every fortnight was followed by 1 year of intermission and then 1 year of the same treatment given for 2 days every 2 months. Compared with matched CF patients, the clinical course, evaluated by Shwachmann scoring, showed less deterioration in the treated group, especially during the year of intensive treatment. Single parameters, such as pulmonary function tests, pulmonary X-ray films, clinical infections, bacterial growth of sputa, and sweat electrolyte concentration, showed no differences. It is concluded that if there is any benefit of this kind of treatment in CF, it has to be very intensive. At present, the psychological stress involved in repeated parenteral administrations over long periods prevents its use in clinical routine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413667     DOI: 10.1097/00005176-198302030-00007

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  6 in total

Review 1.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

2.  Prospective study of serum staphylococcal antibodies in cystic fibrosis.

Authors:  A E Hollsing; M Granström; B Strandvik
Journal:  Arch Dis Child       Date:  1987-09       Impact factor: 3.791

3.  Absorption of safflower oil and structured lipid preparations in patients with cystic fibrosis.

Authors:  V S Hubbard; M C McKenna
Journal:  Lipids       Date:  1987-06       Impact factor: 1.880

4.  Serum fatty acid profiles in cystic fibrosis patients and their parents.

Authors:  A B Christophe; W J Warwick; R T Holman
Journal:  Lipids       Date:  1994-08       Impact factor: 1.880

5.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

Review 6.  Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Authors:  Birgitta Strandvik
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.